Previous 10 | Next 10 |
2023-05-23 07:30:16 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips We’re starting off the day with a breakdown of the biggest pre-market stock movers traders need to watch on Tuesday! Moving stocks are earnings reports, insider buying, delisting pla...
Following the Company’s Fix, Fund, Propel approach, the sale of Preferred Shares totaling $1.1 million to new existing investors underscores improved confidence in Navidea’s progress toward advancing its innovative technology to market. Navidea Biopharmaceuticals, Inc. (NY...
2023-05-11 17:42:35 ET Navidea Biopharmaceuticals ( NYSE: NAVB ) said Thursday it promoted Michael Sherman Blue to the position of chief medical officer. Blue will report directly to the company’s board of directors. Press Release . F...
Following the Company’s Fix, Fund, Propel approach, Dr. Blue’s promotion highlights deep expertise, commitment to quality, and focus on advancement of innovative technology to market. Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the ...
The company introduces Fix, Fund, Propel approach to further focus on strategic objectives; will publish financial and corporate development highlights via press release in lieu of conference call and webcast for Q1 2023 results. Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (&...
Fresh capital for funding Phase IIb and Phase III trials, expands growth, and fuels shareholder value Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agent...
The Asset Purchase Agreement allows Meilleur Technologies, Inc. to develop and commercialize markets while Navidea Biopharmaceuticals, Inc. receives additional liquidity for focused growth. Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Co...
2023-03-31 05:00:30 ET Navidea Biopharmaceuticals ( NYSE: NAVB ) said Michael Rosol stepped down as chief medical officer and the company has hired G2G Ventures as executive consultants to help with its growth plans. The company noted that the chief medical officer's ...
Executive Consulting buttresses senior management’s focus on performance and targeted growth. Chief Medical Officer, Michael Rosol, Ph.D., steps down. Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focuse...
2023-03-21 22:44:05 ET Navidea Biopharmaceuticals, Inc. (NAVB) Q4 2022 Earnings Conference Call March 22, 2023, 17:00 ET Company Participants Michael Rosol - SVP & Chief Medical Officer Erika Eves - VP, Finance & Administration and Principal Financial & A...
News, Short Squeeze, Breakout and More Instantly...
Navidea Biopharmaceuticals Inc. Company Name:
NAVB Stock Symbol:
NYSE Market:
Navidea Biopharmaceuticals, Inc. announced today the filing of Form 15 to voluntarily deregister and suspend SEC reporting obligations. The company maintains strategic focus on its Fix, Fund, Propel approach. Navidea Biopharmaceuticals, Inc. (OTC: NAVB) (“Navidea” or the &...
Navidea Biopharmaceuticals, Inc. and Capital Royalty Partners II, L.P. have entered into a binding settlement agreement and mutual release settling ongoing litigation. Navidea Biopharmaceuticals, Inc. (OTC: NAVB) (“Navidea” or the “Company”), a company focuse...
The Company announced today that the Listings Qualifications Panel of the Committee for Review of the Board of Directors of the NYSE American LLC upheld the NYSE Regulation staff’s previously announced determination to initiate delisting proceedings with respect to the Company’s com...